RecruitingPhase 4NCT06049680

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

Studying Parenteral nutrition-associated cholestasis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Fresenius Kabi
Principal Investigator: Jeffrey Rudolph, MD
University of Pittsburgh
Intervention: SMOFlipid® (lipid injectable emulsion)(drug)
Enrollment: 100 target
Eligibility: 17 years · All sexes
Timeline: 2024 – 2026

Study locations (5)

Emory University Hospital, Atlanta, Georgia, United States
The University of Chicago, Chicago, Illinois, United States
Riley Hospital for Children, Indianapolis, Indiana, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06049680 on ClinicalTrials.gov

Other trials for Parenteral nutrition-associated cholestasis

Additional recruiting or active studies for the same condition.

RECRUITINGNCT06274788
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
Fresenius Kabi

See all trials for Parenteral nutrition-associated cholestasis →

← Back to all trials